What is Regenerx Biopharmaceuticals Sloan Ratio %?
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
As of Mar. 2023, Regenerx Biopharmaceuticals has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
Regenerx Biopharmaceuticals Sloan Ratio % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Regenerx Biopharmaceuticals's Sloan Ratio %
For the Biotechnology subindustry, Regenerx Biopharmaceuticals's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regenerx Biopharmaceuticals's Sloan Ratio % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regenerx Biopharmaceuticals's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Regenerx Biopharmaceuticals's Sloan Ratio % falls into.
Regenerx Biopharmaceuticals Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Regenerx Biopharmaceuticals's Net Income for the trailing twelve months (TTM) ended in Mar. 2023 was -0.546 (Jun. 2022 ) + -0.367 (Sep. 2022 ) + -0.391 (Dec. 2022 ) + -0.385 (Mar. 2023 ) = $-1.69 Mil.
Regenerx Biopharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2023 was -0.219 (Jun. 2022 ) + -0.228 (Sep. 2022 ) + -0.188 (Dec. 2022 ) + -0.189 (Mar. 2023 ) = $-0.82 Mil.
Regenerx Biopharmaceuticals's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2023 was 0 (Jun. 2022 ) + 0 (Sep. 2022 ) + 0 (Dec. 2022 ) + 0 (Mar. 2023 ) = $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regenerx Biopharmaceuticals (OTCPK:RGRX) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Mar. 2023, Regenerx Biopharmaceuticals has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
Regenerx Biopharmaceuticals Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of Regenerx Biopharmaceuticals's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Regenerx Biopharmaceuticals (Regenerx Biopharmaceuticals) Business Description
Regenerx Biopharmaceuticals Inc is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Its operations are confined to one business segment: the development and marketing of product candidates based on Thymosin Beta 4 (Tß4), an amino acid peptide. The company has formulated Tß4 into three distinct product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-137, a topical gel for dermal wounds and reduction of scar tissue; and RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RGRX has been successfully added to your 